NCT04030559View on ClinicalTrials.gov

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene MutationBRIP1 Gene MutationCDK12 Gene MutationCHEK1 Gene MutationCHEK2 Gene MutationDNA Damage Response Gene MutationDNA Repair Gene MutationFANCA Gene MutationFANCD2 Gene MutationFANCL Gene MutationGEN1 Gene MutationNBN Gene MutationProstate CarcinomaRAD51 Gene MutationRAD51C Gene Mutation
Interventions
DRUG

Niraparib

Given PO

DRUG

Niraparib Tosylate Monohydrate

Given PO

PROCEDURE

Radical Prostatectomy

Undergo standard of care surgery

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Janssen, LP

INDUSTRY

lead

Marc Dall'Era, MD

OTHER